Catch-up vaccination safe and effective in children with Kaposiform hemangioendothelioma on sirolimus
Catch-up vaccinations in children with Kaposiform hemangioendothelioma treated with sirolimus were safe and immunogenic.
Phase III
Oncology / Pediatric Hematology
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The study highlights the safety and immunogenicity of catch-up vaccinations in immunocompromised children, which may influence future treatment protocols and vaccine development strategies. This could open new avenues for pharmaceutical companies to address the needs of vulnerable patient populations.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor further studies on vaccine efficacy and safety in similar immunocompromised populations.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.